Core Lab Reports Third Quarter 2021 Results From Continuing Operations:
Core Laboratories N.V. reported Q3 2021 revenue of $118 million and operating income of $6.6 million, with EPS of $0.02. Non-GAAP operating income was $13 million, with an 11% operating margin. Revenue impacted by weather events, project delays, and supply chain issues. Reservoir Description segment revenue was $79 million, while Production Enhancement dropped 3% to $39.2 million. Free Cash Flow rose 33% to $8.8 million. A quarterly dividend of $0.01 per share was declared for Q4 2021.
- Q3 2021 revenue of $118 million, indicating stability.
- Operating income (ex-items) improved by 14% sequentially to $8.6 million in Reservoir Description.
- Free Cash Flow increased by 33% to $8.8 million, affirming positive cash generation.
- Reduction in net debt by $5.4 million, improving the leverage ratio to 2.10.
- Adverse impact from weather events and COVID-19 related project delays.
- Production Enhancement revenue declined by 3%, primarily due to lower international shipments.
AMSTERDAM, Oct. 27, 2021 /PRNewswire/ -- Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA") ("Core", "Core Lab", or the "Company") reported third quarter 2021 revenue of
Core's CEO, Larry Bruno stated, "Core continues to execute on its key strategic objectives by introducing new product and service offerings throughout our global network, and by posting sequential improvements in cash from operations and Free Cash Flow. At the same time, Core reduced net debt during the quarter, further improving the Company's leverage ratio. Operationally, we continue to execute at a high level and were able to expand operating margins in both business segments during the quarter. However, back-to-back named storms along the U.S. Gulf Coast in the third quarter of 2021 adversely affected activity, causing prolonged shutdown of Core's clients' offshore operations and extended power outages at several Company facilities. Additionally, pandemic-related travel restrictions and complications are still affecting the pace of international activity in the Middle East, Asia Pacific and South America regions. As a result of these on-going pandemic-related disruptions, the progress on international projects has been slower than anticipated, moderating expectations for the next several months. However, we see momentum building across all international regions and remain optimistic about the international outlook for 2022 and beyond."
Reservoir Description
Reservoir Description operations are closely correlated with international and offshore activity levels, with approximately
During the third quarter of 2021, under the direction of the CarbonNet Project, Core Lab expanded the laboratory analytical program to include advanced rock and fluid testing on core samples from the Bass Straight, off the southeast coast of Australia. Core's initial analytical program to access this CO2 sequestration opportunity, previously reported in the third quarter of 2020, characterized 300 feet of conventional core from the Gular-1 appraisal well. The expanded program employs Core Lab's proprietary technologies to provide more detailed insight into pore system properties, rock-fluid compatibility, gas and liquid flow behavior, as well as geomechanical properties. The results of this advanced testing will further expand the CarbonNet Project's understanding of the CO2 storage capacity, optimal CO2 injection methodologies and seal integrity, all of which are critical to understanding and reducing geologic risk associated with the project. These data sets will be used to evaluate CO2 injectivity over the life of the project, and to verify proper subsurface containment of the injected CO2. The biggest risk in evaluating any CO2 sequestration project is failing to properly assess the complexity of the targeted subsurface geologic formation and the in situ pore fluids. Core Lab's expertise in evaluating subsurface geology and fluid flow through natural porous media is essential for accessing these types of CO2 sequestration projects.
Core Lab continues to expand laboratory technologies in the Middle East region to meet client demand for rock and fluid laboratory analytical programs. Core remains a key partner by providing critical data sets for evaluating opportunities in both new and mature fields. During the third quarter of 2021, Core's scientists were engaged by a National Oil Company to conduct a comprehensive study involving the analysis of reservoir fluids (crude oil, natural gas and formation water). The properties of these reservoir fluids at a range of subsurface temperature and pressure conditions must be precisely understood in order to predict hydrocarbon recovery over the life of the field. Pressure-Volume-Temperature ("PVT") data sets are used to determine the phase behavior of hydrocarbons at various reservoir stress conditions. As part of this analytical program, Core conducted advanced PVT studies to evaluate the potential injection options for a large-scale Enhanced Oil Recovery ("EOR") program. Although this field is naturally prolific, it is not exempt from physical laws affecting all reservoirs and their inevitable decline. Utilizing Core's proprietary, fully visual PVT cells, Core's scientists precisely determined changes in the physical and compositional properties of the hydrocarbons that will occur over the life of the field. The analytical program is enabling the operator to model reservoir performance, sustain current production levels and optimize ultimate recovery from the reservoir. Further work will be done to evaluate CO2 injection as a source of EOR.
Production Enhancement
Production Enhancement operations, which are focused on complex completions in unconventional, tight-oil reservoirs in the U.S., as well as conventional offshore projects across the globe, posted third quarter 2021 revenue of
During the third quarter of 2021, Core's Production Enhancement segment was approached by a client conducting business in the North Sea to provide plug and abandonment expertise to optimize a slot recovery process through a clean casing recovery program. The slot recovery is a technique that can be used to sidetrack existing wells, allowing access to additional crude oil from untapped or poorly drained reservoir sections, or well abandonment. The traditional method of milling and pulling the well's casing during slot recovery can be costly and time-consuming. The client, after discussion with Core's Production Enhancement engineers, decided to utilize Core's proprietary Plug and Abandonment Perforating System ("PAC™"). PAC™ enables clean casing recovery, allowing for the efficient removal of interior casing strings without risking damage to the outer casing. The PAC™ technology employs an innovative, controlled energetic event that can be configured to penetrate anywhere from one to four casing strings without penetrating or compromising the outer casing. The circumferential coverage provided by the PAC™ technology enables the operator to establish circulation in the annular space between casing strings, facilitating wash operations and the efficient removal of the interior casing. Client feedback indicates the PAC™ system provided greater than
During the third quarter of 2021, Core's completion diagnostic services were called upon by a Permian Basin client to assess a new approach to cementing operations in its horizontal unconventional wells. It is difficult to maintain stage containment when fracing multi-stage laterals in which non-uniform cement placement has occurred. Non-uniform cement placement leaves channels behind pipe through which frac fluid can migrate between targeted intervals. Channels behind pipe can result in some targeted intervals being understimulated. The client wanted to evaluate if casing rotation while cementing would eliminate channels behind pipe. Core utilized its proprietary SpectraStim™ tracers and SpectraScan™ logging technologies to compare the degree of frac fluid containment in a well in which casing rotation was employed during the cementing operation. The well was then compared with adjacent wells in which no casing rotation had been employed. Core's completion diagnostics engineers were able to confirm more uniform cement placement and better containment of frac fluid when pipe rotation was employed. In comparing oil production between the rotated pipe well and the wells in which no pipe rotation had been performed, the client observed an increase of 800 barrels of oil per 1000 feet of treated well in the first 80 days of production from the rotated pipe well. With these favorable results, the operator elected to implement pipe rotation in subsequent cementing operations. Core's completion diagnostic technologies continue to assist operators in evaluating innovations in completion techniques.
Free Cash Flow and Dividend
Core continues to focus on generating free cash flow ("FCF"), a non-GAAP financial measure defined as cash from operations less capital expenditures. For the third quarter of 2021, cash from operations increased
For the third quarter of 2021, after funding the quarterly dividend, free cash was primarily used for reducing net debt by
On 28 July 2021, Core's Board of Supervisory Directors ("Board") announced a quarterly cash dividend of
On 27 October 2021, the Board approved a cash dividend of
Return On Invested Capital
The Board and the Company's Executive Management continue to focus on strategies that maximize return on invested capital ("ROIC") and FCF, factors that have high correlation to total shareholder return. Core's commitment to an asset-light business model and disciplined capital stewardship promote capital efficiency and are designed to produce more predictable and superior long-term ROIC.
The Board has established an internal performance metric of demonstrating superior ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg, as the Company continues to believe superior ROIC will result in higher total return to shareholders. As of 30 September 2021, Core Lab's ROIC was
Industry and Core Lab Outlook and Guidance
The global crude-oil market continues to tighten, as demand for crude oil continues to approach pre-COVID levels, resulting in noticeable increases to crude-oil commodity prices. Current crude-oil commodity prices may also drive a higher level of investment, and urgency, in international offshore crude-oil development projects in 2022 and beyond. These crude-oil market fundamentals are reflected in the gradual increase in the international rig count, with more oilfield equipment coming under contract. Core sees this as a leading indicator of a growing international cycle.
With Core Lab having more than
International revenue for the third quarter 2021 was up
Core projects fourth quarter 2021 revenue to range from
The Company's fourth quarter 2021 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange. Fourth quarter 2021 guidance also assumes an effective tax rate of
Earnings Call Scheduled
The Company has scheduled a conference call to discuss Core's third quarter 2021 earnings announcement. The call will begin at 7:30 a.m. CDT / 2:30 p.m. CEST on Thursday, 28 October 2021. To listen to the call, please go to Core's website at www.corelab.com.
Core Laboratories N.V. is a leading provider of proprietary and patented reservoir description and production enhancement services and products used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in the world. This release, as well as other statements we make, includes forward-looking statements regarding the future revenue, profitability, business strategies and developments of the Company made in reliance upon the safe harbor provisions of Federal securities law. The Company's outlook is subject to various important cautionary factors, including risks and uncertainties related to the oil and natural gas industry, business conditions, international markets, international political climates, public health crises, such as the COVID-19 pandemic, and any related actions taken by businesses and governments, and other factors as more fully described in the Company's most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the U.S. Securities and Exchange Commission. These important factors could cause the Company's actual results to differ materially from those described in these forward-looking statements. Such statements are based on current expectations of the Company's performance and are subject to a variety of factors, some of which are not under the control of the Company. Because the information herein is based solely on data currently available, and because it is subject to change as a result of changes in conditions over which the Company has no control or influence, such forward-looking statements should not be viewed as assurance regarding the Company's future performance.
The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.
Visit the Company's website at www.corelab.com. Connect with Core Lab on Facebook, LinkedIn and YouTube.
CORE LABORATORIES N.V. & SUBSIDIARIES | |||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||||
(amounts in thousands, except per share data) | |||||||||||||||||
(Unaudited) | |||||||||||||||||
Three Months Ended | % Variance | ||||||||||||||||
September 30, | June 30, | September 30, | vs. Q2-21 | vs. Q3-20 | |||||||||||||
REVENUE | $ | 117,985 | $ | 118,745 | $ | 105,382 | (0.6)% | ||||||||||
OPERATING EXPENSES: | |||||||||||||||||
Costs of services and sales | 92,918 | 93,841 | 81,038 | (1.0)% | |||||||||||||
General and administrative expense | 15,115 | 9,670 | 8,937 | ||||||||||||||
Depreciation and amortization | 4,496 | 4,751 | 5,164 | (5.4)% | (12.9)% | ||||||||||||
Other (income) expense, net | (1,184) | (2,317) | (1,088) | NM | NM | ||||||||||||
Total operating expenses | 111,345 | 105,945 | 94,051 | ||||||||||||||
OPERATING INCOME (LOSS) | 6,640 | 12,800 | 11,331 | (48.1)% | (41.4)% | ||||||||||||
Interest expense | 2,669 | 2,530 | 4,672 | (42.9)% | |||||||||||||
Income (loss) from continuing operations before income tax expense | 3,971 | 10,270 | 6,659 | (61.3)% | (40.4)% | ||||||||||||
Income tax expense (benefit) | 2,962 | 2,053 | 3,663 | (19.1)% | |||||||||||||
Income (loss) from continuing operations | 1,009 | 8,217 | 2,996 | (87.7)% | (66.3)% | ||||||||||||
Income (loss) from discontinued operations, net of income taxes | — | — | — | NM | NM | ||||||||||||
Net income (loss) | 1,009 | 8,217 | 2,996 | (87.7)% | (66.3)% | ||||||||||||
Net income (loss) attributable to non- | 135 | 157 | 33 | (14.0)% | |||||||||||||
Net income (loss) attributable to Core | $ | 874 | $ | 8,060 | $ | 2,963 | (89.2)% | (70.5)% | |||||||||
Diluted earnings (loss) per share from | $ | 0.02 | $ | 0.17 | $ | 0.07 | (88.2)% | (71.4)% | |||||||||
Diluted earnings (loss) per share | $ | 0.02 | $ | 0.17 | $ | 0.07 | (88.2)% | (71.4)% | |||||||||
Weighted average common shares | 47,125 | 47,103 | 44,899 | —% | |||||||||||||
Effective tax rate | 75 | % | 20 | % | 55 | % | NM | NM | |||||||||
SEGMENT INFORMATION: | |||||||||||||||||
Revenue: | |||||||||||||||||
Reservoir Description | $ | 78,775 | $ | 78,252 | $ | 80,060 | (1.6)% | ||||||||||
Production Enhancement | 39,210 | 40,493 | 25,322 | (3.2)% | |||||||||||||
Total | $ | 117,985 | $ | 118,745 | $ | 105,382 | (0.6)% | ||||||||||
Operating income (loss): | |||||||||||||||||
Reservoir Description | $ | 4,425 | $ | 7,265 | $ | 11,022 | (39.1)% | (59.9)% | |||||||||
Production Enhancement | 2,779 | 3,831 | (321) | (27.5)% | NM | ||||||||||||
Corporate and Other | (564) | 1,704 | 630 | NM | NM | ||||||||||||
Total | $ | 6,640 | $ | 12,800 | $ | 11,331 | (48.1)% | (41.4)% | |||||||||
"NM" means not meaningful |
CORE LABORATORIES N.V. & SUBSIDIARIES | ||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||
(amounts in thousands, except per share data) | ||||||||||
(Unaudited) | ||||||||||
Nine Months Ended | % Variance | |||||||||
2021 | 2020 | |||||||||
REVENUE | $ | 345,113 | $ | 373,518 | (7.6)% | |||||
OPERATING EXPENSES: | ||||||||||
Costs of services and sales | 270,909 | 286,849 | (5.6)% | |||||||
General and administrative expense | 33,246 | 37,725 | (11.9)% | |||||||
Depreciation and amortization | 14,118 | 16,030 | (11.9)% | |||||||
Impairments, inventory write-down and other charges | — | 132,136 | NM | |||||||
Other (income) expense, net | (4,222) | 987 | NM | |||||||
Total operating expenses | 314,051 | 473,727 | (33.7)% | |||||||
OPERATING INCOME (LOSS) | 31,062 | (100,209) | NM | |||||||
Interest expense | 6,562 | 11,452 | (42.7)% | |||||||
Income (loss) from continuing operations before income tax expense | 24,500 | (111,661) | NM | |||||||
Income tax expense (benefit) | 7,068 | (644) | NM | |||||||
Income (loss) from continuing operations | 17,432 | (111,017) | NM | |||||||
Income (loss) from discontinued operations, net of income taxes | — | — | NM | |||||||
Net income (loss) | 17,432 | (111,017) | NM | |||||||
Net income (loss) attributable to non-controlling interest | 393 | 157 | ||||||||
Net income (loss) attributable to Core Laboratories N.V. | $ | 17,039 | $ | (111,174) | NM | |||||
Diluted earnings (loss) per share from continuing operations | $ | 0.37 | $ | (2.50) | NM | |||||
Diluted earnings (loss) per share attributable to Core Laboratories N.V. | $ | 0.36 | $ | (2.50) | NM | |||||
Weighted average common shares outstanding - assuming dilution | 46,833 | 44,470 | ||||||||
Effective tax rate | 29 | % | 1 | % | ||||||
SEGMENT INFORMATION: | ||||||||||
Revenue: | ||||||||||
Reservoir Description | $ | 233,512 | $ | 271,203 | (13.9)% | |||||
Production Enhancement | 111,601 | 102,315 | ||||||||
Total | $ | 345,113 | $ | 373,518 | (7.6)% | |||||
Operating income (loss): | ||||||||||
Reservoir Description | $ | 21,742 | $ | 35,618 | (39.0)% | |||||
Production Enhancement | 8,170 | (137,944) | NM | |||||||
Corporate and Other | 1,150 | 2,117 | NM | |||||||
Total | $ | 31,062 | $ | (100,209) | NM | |||||
"NM" means not meaningful |
CORE LABORATORIES N.V. & SUBSIDIARIES | |||||||||||||||||
CONDENSED CONSOLIDATED BALANCE SHEET | |||||||||||||||||
(amounts in thousands) | |||||||||||||||||
(Unaudited) | |||||||||||||||||
% Variance | |||||||||||||||||
ASSETS: | September 30, | June 30, | December | vs. Q2-21 | vs. Q4-20 | ||||||||||||
Cash and cash equivalents | $ | 19,050 | $ | 33,617 | $ | 13,806 | (43.3)% | ||||||||||
Accounts receivable, net | 95,297 | 93,217 | 83,192 | ||||||||||||||
Inventories | 44,056 | 38,946 | 38,151 | ||||||||||||||
Other current assets | 28,842 | 35,369 | 30,699 | (18.5)% | (6.0)% | ||||||||||||
Total current assets | 187,245 | 201,149 | 165,848 | (6.9)% | |||||||||||||
Property, plant and equipment, net | 112,736 | 112,398 | 115,293 | (2.2)% | |||||||||||||
Right of use assets | 65,379 | 66,482 | 66,385 | (1.7)% | (1.5)% | ||||||||||||
Intangibles, goodwill and other long-term assets, net | 220,919 | 218,396 | 221,053 | (0.1)% | |||||||||||||
Total assets | $ | 586,279 | $ | 598,425 | $ | 568,579 | (2.0)% | ||||||||||
LIABILITIES AND EQUITY: | |||||||||||||||||
Accounts payable | $ | 35,015 | $ | 30,383 | $ | 23,028 | |||||||||||
Short-term operating lease liabilities | 12,191 | 12,150 | 11,437 | ||||||||||||||
Other current liabilities | 45,747 | 48,321 | 55,285 | (5.3)% | (17.3)% | ||||||||||||
Total current liabilities | 92,953 | 90,854 | 89,750 | ||||||||||||||
Long-term debt, net | 188,463 | 208,305 | 259,433 | (9.5)% | (27.4)% | ||||||||||||
Long-term operating lease liabilities | 53,831 | 55,121 | 56,108 | (2.3)% | (4.1)% | ||||||||||||
Other long-term liabilities | 90,018 | 89,801 | 87,715 | ||||||||||||||
Total equity | 161,014 | 154,344 | 75,573 | ||||||||||||||
Total liabilities and equity | $ | 586,279 | $ | 598,425 | $ | 568,579 | (2.0)% | ||||||||||
"NM" means not meaningful |
CORE LABORATORIES N.V. & SUBSIDIARIES | |||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||
(amounts in thousands) | |||||||||
(Unaudited) | |||||||||
Nine Months Ended September 30, | |||||||||
2021 | 2020 | ||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||||
Income (loss) from continuing operations | $ | 17,432 | $ | (111,017) | |||||
Income (loss) from discontinued operations | — | — | |||||||
Net Income (loss) | $ | 17,432 | $ | (111,017) | |||||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||
Stock-based compensation | 16,646 | 16,254 | |||||||
Depreciation and amortization | 14,118 | 16,030 | |||||||
Deferred income taxes | 3,058 | (13,014) | |||||||
Impairments, inventory write-down and other charges | — | 132,136 | |||||||
Gain on sale of business | (1,012) | — | |||||||
Accounts receivable | (12,135) | 45,229 | |||||||
Inventories | (3,599) | (2,880) | |||||||
Accounts payable | 9,661 | (13,262) | |||||||
Other adjustments to net income (loss) | (14,744) | 238 | |||||||
Net cash provided by operating activities | $ | 29,425 | $ | 69,714 | |||||
CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||||
Capital expenditures | $ | (8,789) | $ | (8,578) | |||||
Proceeds from sale of business, net of cash sold | 513 | — | |||||||
Other investing activities | 1,747 | (952) | |||||||
Net cash used in investing activities | $ | (6,529) | $ | (9,530) | |||||
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||||
Repayment of debt borrowings | $ | (194,000) | $ | (71,000) | |||||
Proceeds from debt borrowings | 123,000 | 30,000 | |||||||
Proceeds from issuance of common shares | 60,000 | — | |||||||
Transaction costs related to issuance of common shares | (861) | — | |||||||
Dividends paid | (1,372) | (12,001) | |||||||
Repurchase of common shares | (3,911) | (1,593) | |||||||
Other financing activities | (508) | (1,536) | |||||||
Net cash used in financing activities | $ | (17,652) | $ | (56,130) | |||||
NET CHANGE IN CASH AND CASH EQUIVALENTS | 5,244 | 4,054 | |||||||
CASH AND CASH EQUIVALENTS, beginning of period | 13,806 | 11,092 | |||||||
CASH AND CASH EQUIVALENTS, end of period | $ | 19,050 | $ | 15,146 |
Non-GAAP Information
Management believes that the exclusion of certain income and expenses enables it to evaluate more effectively the Company's operations period-over-period and to identify operating trends that could otherwise be masked by the excluded Items. For this reason, we use certain non-GAAP measures that exclude these Items; and we feel that this presentation provides a clearer comparison with the results reported in prior periods. The non-GAAP financial measures should be considered in addition to, and not as a substitute for, the financial results prepared in accordance with GAAP, as more fully discussed in the Company's financial statement and filings with the Securities and Exchange Commission.
Reconciliation of Operating Income (Loss), Income (Loss) from Continuing Operations and | ||||||||||||
(amounts in thousands, except per share data) | ||||||||||||
(Unaudited) | ||||||||||||
Operating Income (loss) from Continuing Operations | ||||||||||||
Three Months Ended | ||||||||||||
September 30, 2021 | June 30, 2021 | September 30, 2020 | ||||||||||
GAAP reported | $ | 6,640 | $ | 12,800 | $ | 11,331 | ||||||
Stock compensation 1 | 6,506 | — | — | |||||||||
Foreign exchange losses (gains) | (140) | 352 | 982 | |||||||||
Excluding specific items | $ | 13,006 | $ | 13,152 | $ | 12,313 | ||||||
Income (loss) from Continuing Operations | ||||||||||||
Three Months Ended | ||||||||||||
September 30, 2021 | June 30, 2021 | September 30, 2020 | ||||||||||
GAAP reported | $ | 1,009 | $ | 8,217 | $ | 2,996 | ||||||
Stock compensation 1 | 6,506 | — | — | |||||||||
Debt restructuring | — | — | 1,223 | |||||||||
Impact of higher (lower) tax rate 2 | 867 | — | 2,773 | |||||||||
Foreign exchange losses (gains) | (111) | 281 | 344 | |||||||||
Excluding specific items | $ | 8,271 | $ | 8,498 | $ | 7,336 | ||||||
Diluted Earnings (Loss) Per Share from Continuing Operations | ||||||||||||
Three Months Ended | ||||||||||||
September 30, 2021 | June 30, 2021 | September 30, 2020 | ||||||||||
GAAP reported | $ | 0.02 | $ | 0.17 | $ | 0.07 | ||||||
Stock compensation 1 | 0.14 | — | — | |||||||||
Debt restructuring | — | — | 0.03 | |||||||||
Impact of higher (lower) tax rate 2 | 0.02 | — | 0.06 | |||||||||
Foreign exchange losses (gains) | — | 0.01 | — | |||||||||
Excluding specific items | $ | 0.18 | $ | 0.18 | $ | 0.16 | ||||||
(1) | Three months ended September 30, 2021 includes stock compensation expense recognized pursuant to FASB ASC 718 "Stock |
(2) | Three months ended September 30, 2021 and 2020 includes adjustments to reflect tax expense at a normalized rate of |
Segment Information | ||||||||||||
(amounts in thousands) | ||||||||||||
(Unaudited) | ||||||||||||
Operating Income (Loss) from Continuing Operations | ||||||||||||
Three Months Ended September 30, 2021 | ||||||||||||
Reservoir | Production | Corporate and | ||||||||||
GAAP reported | $ | 4,425 | $ | 2,779 | $ | (564) | ||||||
Foreign exchange losses | (267) | 109 | 18 | |||||||||
Stock compensation | 4,420 | 2,086 | — | |||||||||
Excluding specific items | $ | 8,578 | $ | 4,974 | $ | (546) |
Return on Invested Capital
Return on Invested Capital ("ROIC") is presented based on our belief that this non-GAAP measure is useful information to investors and management when comparing our profitability and the efficiency with which we have employed capital over time relative to other companies. ROIC is not a measure of financial performance under GAAP and should not be considered as an alternative to net income.
ROIC is defined by Bloomberg as Net Operating Profit (Loss) ("NOP") less Cash Operating Tax ("COT") divided by Total Invested Capital ("TIC"), where NOP is defined as GAAP net income before minority interest plus the sum of income tax expense, interest expense, and pension expense less pension service cost and COT is defined as income tax expense plus the sum of the change in net deferred taxes, and the tax effect on interest expense and TIC is defined as GAAP stockholder's equity plus the sum of net long-term debt, lease liabilities, allowance for doubtful accounts, net balance of deferred taxes, and income tax payable.
The Board has established an internal performance metric of demonstrating superior ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg. As of 30 September 2021, Core's calculation of ROIC using Bloomberg's formula, as described above, was
Free Cash Flow
Core uses the non-GAAP measure of free cash flow to evaluate its cash flows and results of operations. Free cash flow is an important measurement because it represents the cash from operations, in excess of capital expenditures, available to operate the business and fund non-discretionary obligations. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative consideration to operating income, net income, earnings per share, or cash flows from operating, investing, or financing activities, each as determined in accordance with GAAP. Free cash flow should not be considered a measure of liquidity. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented may not be comparable to similarly titled measures presented by other companies.
Computation of Free Cash Flow | |||||||||
(amounts in thousands) | |||||||||
(Unaudited) | |||||||||
Three Months Ended | Nine Months Ended | ||||||||
September 30, 2021 | September 30, 2021 | ||||||||
Net cash provided by operating activities | $ | 11,952 | $ | 29,425 | |||||
Capital expenditures | (3,132) | (8,789) | |||||||
Free cash flow | $ | 8,820 | $ | 20,636 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/core-lab-reports-third-quarter-2021-results-from-continuing-operations-301410272.html
SOURCE Core Laboratories N.V.
FAQ
What were Core Laboratories' Q3 2021 earnings results (CLB)?
What is the future outlook for Core Laboratories (CLB) after Q3 2021?
What were the impacts of weather events on Core Laboratories (CLB) results?
What is the cash flow situation of Core Laboratories (CLB)?